Eur Heart J:美国主动脉瓣狭窄介入治疗的当代趋势

2020-03-01 不详 MedSci原创

本研究的目的旨在评估美国在引进经导管主动脉瓣置换术(TAVI)前后主动脉狭窄(AS)介入治疗的当代趋势。本研究纳入分析了2003-2016年美国接受治疗的AS患者,在年龄>60岁的患者中,AS的介入治疗率从96/100000人增至137/100000人,P<0.001。AS介入治疗的住院花费从2003年的22.8亿美元增至2016年的43.3亿美元,P<0.001。在接受主动脉瓣置换术

本研究的目的旨在评估美国在引进经导管主动脉瓣置换术(TAVI)前后主动脉狭窄(AS)介入治疗的当代趋势。

本研究纳入分析了2003-2016年美国接受治疗的AS患者,在年龄>60岁的患者中,AS的介入治疗率从96/100000人增至137/100000人,P<0.001。AS介入治疗的住院花费从2003年的22.8亿美元增至2016年的43.3亿美元,P<0.001。在接受主动脉瓣置换术治疗的患者中,TAVI的比例从2012年的11.9%增至2016年的43.2%,P<0.001。相比于女性和白种人,男性和西班牙裔患者的TAVI比例更低。TAVI的院内死亡率从2012年的4.7%降至2016年的2.2%,P<0.001。TAVI术后的透析、永久起搏器植入和输血的发生率也逐年降低。然后,术后卒中的发生率无明显变化。

研究结果显示,在美国,主动脉瓣狭窄介入治疗的比例逐年增高,主动脉瓣置换术的治疗模式也逐渐转变。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1332716, encodeId=c5f31332e1675, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357413, encodeId=d5f4135e4134a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415622, encodeId=49a214156223d, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563238, encodeId=51dd15632388a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1332716, encodeId=c5f31332e1675, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357413, encodeId=d5f4135e4134a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415622, encodeId=49a214156223d, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563238, encodeId=51dd15632388a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
    2020-03-03 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1332716, encodeId=c5f31332e1675, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357413, encodeId=d5f4135e4134a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415622, encodeId=49a214156223d, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563238, encodeId=51dd15632388a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1332716, encodeId=c5f31332e1675, content=<a href='/topic/show?id=1dd6231822d' target=_blank style='color:#2F92EE;'>#主动脉瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23182, encryptionId=1dd6231822d, topicName=主动脉瓣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357413, encodeId=d5f4135e4134a, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415622, encodeId=49a214156223d, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563238, encodeId=51dd15632388a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Mar 03 08:04:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
    2020-03-03 slcumt

相关资讯

JACC:生物瓣膜血栓形成患者远期的抗凝预后研究

在生物瓣膜血栓形成(BPVT)的早期预防和治疗中,抗凝是有效的,但BPVT后的长期疗效尚不清楚。本研究的目的旨在评估接受抗凝治疗的BPVT患者的远期预后。本研究纳入分析了83名因疑似BPVT接受华法林治疗的患者(平均年龄57±18岁,男性占54%),并与166名匹配对照进行对比分析。有62名患者在抗凝治疗后的3个月内心超结果转为正常,21名患者对华法林无反应。经过平均34个月时间的随访,病例组和对

JACC:国内学者揭示年龄-性别在血管硬化中的交互作用

动脉硬化是血管老化过程的中心环节。传统上,血管研究主要集中在动脉粥样硬化性血管疾病上,而动脉僵硬并没有引起太多的关注。本研究的目的是评估面临心血管疾病高负担的中国人群动脉硬化的终生轨迹,尤其是年龄-性别的相互作用和潜在的决定因素。本研究纳入分析了80415名检测过肱踝脉搏波速度(baPWV)的正常人群,结果表明年龄相关的动脉硬化程度存在性别差异,从青春期到58岁的男性血管硬化程度更高,而此后的女性

JACC:复发心梗的造血和免疫反应远小于第一次心梗

反复心梗在冠心病患者中比较常见,且与死亡率增高相关。骨髓祖细胞的长期重编程发生在对炎症刺激的反应中,且会在机体对继发性炎症反应后发生改变。本研究的目的旨在评估反复心梗对骨髓刺激和炎症反应的影响。本研究开发了一种可以在同一只小鼠进行连续2次模型不同左室区域心梗的手术方法,通过结扎左回旋动脉,再结扎左冠状动脉前降支,造成复发心肌梗死。第一次心肌梗死通过循环信号诱导骨髓的"记忆",降低骨髓巨噬细胞造血维

JACC:携带FBN1致病性变异马凡综合征患者的主动脉风险研究

马凡综合征患者的主动脉风险尚未评估,FBN1基因的致病性变异也未被证实。本研究的目的旨在评估Marfan综合征患者的主动脉风险,以及FBN1基因的致病性变异与主动脉根部直径的相关性。本研究纳入分析了包含FBN1基因的致病性变异的954名患者(女性占54%,平均年龄23岁),在长达9.1年时间的随访期间,142名患者接受了预防性的主动脉根部手术,5名患有A型主动脉夹层,12名死亡。当主动脉根部直径&

盘点:JACC3月第一期研究一览

1. 携带FBN1致病性变异马凡综合征患者的主动脉风险研究DOI: 10.1016/j.jacc.2019.12.043http://www.onlinejacc.org/content/75/8?current-issue=y马凡综合征患者的主动脉风险尚未评估,FBN1基因的致病性变异也未被证实。本研究的目的旨在评估Marfan综合征患者的主动脉风险,以及FBN1基因的致病性变异与主动脉根部直径

Heart:房缺封堵和肺动脉瓣置换术可降低患者三尖瓣反流程度

心脏手术或导管介入治疗是目前常见的减少成人先天性心脏病右心室容积负荷的方法,然而,这些方法对患者已有的三尖瓣反流(TR)的影响尚不清楚。本研究目的旨在评估房间隔缺损(ASD)封堵和肺动脉瓣置换术(PVR)后TR严重程度的潜在降低。本研究纳入分析了162名患者(手术时的平均年龄为41.6±16.1岁,男性占38.3%),其中101名接受了ASD封堵术,61名接受了PVR术,仅有11.1%的患者同时接